AGFS yields 66.67% · ABBV yields 3.06%● Live data
📍 AGFS pulled ahead of the other in Year 1
Combined, AGFS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGFS + ABBV for your $10,000?
AgroFresh Solutions, Inc. provides science-based solutions, data-driven technologies, and high-touch customer services. The company's flagship product is the SmartFresh system that regulates the post-harvest ripening effects of ethylene to preserve the texture, firmness, taste, and appearance of produce during storage, transportation, and retail display. It also provides Harvista technology for use in near-harvest management of apples, pears, cherries, and blueberries; FreshCloud, a digital technology service platform of produce monitoring and screening solutions; and LandSpring, a 1- methlycycloproprene technology targeted to transplanted vegetable seedlings. In addition, the company offers fungicides, disinfectants, coatings, and packinghouse equipment for the citrus market under the Actiseal, FreshStart, VitaFresh Botanicals, Teycer Originals, and Control-Tec brands. It supports growers, packers, and retailers with solutions across the food supply chain to enhance the shelf life of fresh produce. The company primarily operates in the United States, Canada, Argentina, Brazil, Chile, Columbia, Costa Rica, the Dominican Republic, Ecuador, Guatemala, Mexico, Peru, Uruguay, Europe, the Middle East, Africa, Australia, China, India, Japan, New Zealand, South Korea, and the Philippines. AgroFresh Solutions, Inc. was founded in 1994 and is headquartered in Philadelphia, Pennsylvania.
Full AGFS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.